Results 21 to 30 of about 5,215,493 (360)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Journal of Hematology & Oncology, 2023
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies.
Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yang Li   +4 more
semanticscholar   +1 more source

Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. [PDF]

, 2018
Both adjuvants and focal ablation can alter the local innate immune system and trigger a highly effective systemic response. Our goal is to determine the impact of these treatments on directly treated and distant disease and the mechanisms for the ...
Borowsky, Alexander D, Chavez, Michael, Davis, Ryan R, Ferrara, Katherine W, Fite, Brett Z, Hubbard, Neil E, Ilovitsh, Asaf, Ingham, Elizabeth S, Mahakian, Lisa M, Monjazeb, Arta M, Murphy, William J, Silvestrini, Matthew T, Tam, Sarah M, Tepper, Clifford G   +13 more
core   +1 more source

ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism

OncoImmunology, 2017
Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach, Jan Winter, Miriam Reuschenbach, Renata Blatnik, Alexandra Klevenz, Miriam Bertrand, Stephanie Hoppe, Magnus von Knebel Doeberitz, Agnieszka K. Grabowska, Angelika B. Riemer   +9 more
doaj   +1 more source

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Frontiers in Pharmacology, 2023
Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated ...
Yosuke Shibata, Takeshi Kishida, Taku Kouro, Taku Kouro, Feifei Wei, Feifei Wei, Yuka Igarashi, Yuka Igarashi, Hidetomo Himuro, Hidetomo Himuro, Takeaki Noguchi, Mitsuyuki Koizumi, Takahisa Suzuki, Kimito Osaka, Yusuke Saigusa, Tetsuro Sasada, Tetsuro Sasada   +16 more
doaj   +1 more source

CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy

Nature, 2019
Cancer immunotherapy restores or enhances the effector function of CD8+ T cells in the tumour microenvironment1,2. CD8+ T cells activated by cancer immunotherapy clear tumours mainly by inducing cell death through perforin–granzyme and Fas–Fas ligand ...
Weimin Wang, Michael F. Green, J. E. Choi, M. Gijon, Paul D. Kennedy, Jeffrey K. Johnson, P. Liao, Xueting Lang, Ilona Kryczek, Amanda Sell, Houjun Xia, Jiajia Zhou, Gaopeng Li, Jing Li, Wei Li, Shuang Wei, Linda Vatan, Hongjuan Zhang, Wojciech Szeliga, W. Gu, Rebecca J Liu, T. Lawrence, Candice Lamb, Yuri Tanno, M. Cieslik, E. Stone, G. Georgiou, T. Chan, A. Chinnaiyan, W. Zou   +29 more
semanticscholar   +1 more source

Emerging phagocytosis checkpoints in cancer immunotherapy

Signal Transduction and Targeted Therapy, 2023
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as it utilizes patients’ own immune systems in combating the cancer cells.
Yue-Ying Liu, Yanjin Wang, Yanrong Yang, Linjun Weng, Qi Wu, Jin Zhang, Pengcheng Zhao, L. Fang, Yufeng Shi, Ping Wang   +9 more
semanticscholar   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model

OncoImmunology, 2019
Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages.
Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier, Angelika B. Riemer   +11 more
doaj   +1 more source

Beyond the immune suppression: the immunotherapy in prostate cancer [PDF]

, 2015
Prostate cancer (PCa) is the second most common cancer in men.Aswell in many other human cancers, inflammation and immune suppression have an important role in their development.We briefly describe the host components that interact with the tumor to ...
Agliano', Anna Maria, Cattarino, Susanna, Collalti, Giulia, Sciarra, Alessandro, Silvestri, Ida   +4 more
core   +3 more sources

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Molecular Cancer, 2023
Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal component of the tumor microenvironment.
Hao Zhang, Xinghai Yue, Zhe Chen, Chao Liu, Wantao Wu, Nan Zhang, Zao-bin Liu, Liping Yang, Qing Jiang, Quan Cheng, Peng Luo, Guodong Liu   +11 more
semanticscholar   +1 more source